NextCompany

$1.08 Million ARR Lifestyle Medical CRM with Seller Seeking to Retain Equity and Open to an Earn-Out

Medical CRM Software with Three-Year Subscription Contracts

On NextCompany since August 27, 2026 (48 days)

Location undisclosed6 FT employees
Financial summary
Asking price
N/A
Gross revenue
$1,080,000
Cash flow (SDE)
N/A
EBITDA
$320,000

Figures come from the listing party and are not verified or guaranteed by NextCompany. Parts of this page are AI-generated and may contain errors. Verify everything before relying on it. See the Buyer Terms.

Business overview

A U.S. medical software company provides web-based CRM solutions for physicians, surgeons, and lifestyle medicine professionals. Subscription contracts run for a minimum of three years. Practices focused on medical weight loss, obesity, and chronic disease management subscribe. Revenue grew from $283,956 in 2021 to over $331,047 in 2023. Projected 2026 ARR reaches $1,080,000 with $320,000 EBITDA. Six full-time employees and independent contractors form the team. The founder seeks a strategic partner and remains open to earn-out, majority-stake sale, or rollover equity.

Who is a good fit for this business

  • Buyers seeking B2B SaaS companies in medical CRM with recurring revenue match this profile.
  • Acquirers open to earn-out structures and founder rollover evaluate this software business.
  • Strategic partners targeting lifestyle medicine practices with six-employee teams pursue this opportunity.

Details

Reason for selling
The founder is seeking a strategic partner and financial sponsor to help scale the company.

Frequently Asked Questions

Projected 2026 ARR reaches $1,080,000. EBITDA totals $320,000. Revenue grew from $283,956 in 2021.

Subscription contracts run for a minimum of three years. The company serves practices in medical weight loss and chronic disease management.

Six full-time employees and independent contractors form the team. A CTO oversees technical programs. The entire team remains after acquisition.

The founder seeks a strategic partner and financial sponsor. Options include earn-out based on 2026 numbers, majority-stake sale, and rollover equity.

Similar businesses